Document Detail


Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
MedLine Citation:
PMID:  18069029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is now emerging that, in patients who are at high risk for cardiovascular complications and, in particular, those with diabetes, the occurrence of late restenosis and thrombosis after treatment of coronary artery disease with drug-eluting stents is higher than earlier reports have suggested. Therefore, the aim of this study was to assess the prevalence of in-stent restenosis in a cohort of consecutive patients with diabetes treated for coronary disease in 2005 with drug-eluting stents [either sirolimus (58%) or paclitaxel (42%)]. The duration of follow-up was 9.0+/-3.4 months [mean+/-1 standard deviation (S.D.)]. A total of 154 patients (type 2 diabetes: 91%) were included in the study (age: 66+/-10 years), and the total number of implanted stents was 184. Two subjects died from cardiac causes, while myocardial infarction and (un)stable angina were observed in 3 (2%) and 39 (25%) patients, respectively. In-stent restenosis, appraised by angiography, was observed in 17 individuals (11%) after a mean follow-up of five months. Mean HbA(1c) in patients with restenosis was 7.6+/-1.8%. There was no difference in the rate of restenosis with sirolimus-(n=8) compared with paclitaxel-(n=9) eluting stents. Male gender, oral therapy for diabetes and stent diameter were predictors of in-stent restenosis. In conclusion, even over a medium-term period, in-stent restenosis remains a potential risk for coronary diabetic patients treated with drug-eluting devices.
Authors:
M Kitoga; A Pasquet; V Preumont; J Kefer; M-P Hermans; J-L Vanoverschelde; M Buysschaert
Related Documents :
11340009 - Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis.
12410499 - Balloon-based radiation therapy for treatment of in-stent restenosis in human coronary ...
17441309 - Comparison of short- and long-term outcomes between cypher and taxus drug-eluting stent...
19166689 - Impact of left ventricular dysfunction on hospital mortality among patients undergoing ...
22009909 - Arthroscopically assisted treatment of adolescent knee joint tuberculosis.
19018239 - Impact of direct sirolimus-eluting stent implantation on the early systemic inflammator...
21455329 - Does deep sedation impact the results of 48 hours catheterless ph testing?
6877009 - Endolymphatic subarachnoid shunt operation for idiopathic endolymphatic hydrops.
21334639 - Long-term effect on quality of life of repeat detrusor injections of botulinum neurotox...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Diabetes & metabolism     Volume:  34     ISSN:  1262-3636     ISO Abbreviation:  Diabetes Metab.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-19     Completed Date:  2008-05-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607599     Medline TA:  Diabetes Metab     Country:  France    
Other Details:
Languages:  eng     Pagination:  62-7     Citation Subset:  IM    
Affiliation:
Service d'endocrinologie et nutrition, université catholique de Louvain, cliniques universitaires Saint-Luc, 10, avenue Hippocrate, 1200 Bruxelles, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cohort Studies
Coronary Restenosis / epidemiology*,  mortality
Coronary Stenosis / therapy*
Diabetes Mellitus, Type 1 / therapy
Diabetes Mellitus, Type 2 / therapy
Diabetic Angiopathies / therapy*
Drug-Eluting Stents*
Female
Humans
Immunosuppressive Agents / therapeutic use
Male
Middle Aged
Retrospective Studies
Sirolimus / therapeutic use*
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of simultaneous dual-site TENS stimulation on experimental pain.
Next Document:  Adiponectin: an update.